A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

1I. S. Babina and N. C. Turner, Advances and challenges in targeting FGFR signalling in cancer, Nat. Rev. Cancer 17 (2017) 318–332; https://doi.org/10.1038/nrc.2017.8Search in Google Scholar

2Q. Liang, J. Wang, L. Zhao, J. Hou, Y. Hu and J. Shi, Recent advances of dual FGFR inhibitors as a novel therapy for cancer, Eur. J. Med. Chem. 214 (2021) Article ID 113205; https://doi.org/10.1016/j.ejmech.2021.113205Search in Google Scholar

3J. Zheng, W. Zhang, L. Li, Yi He, Y. Wei, Y. Dang, S. Nie and Z. Guo, Signaling pathway and small-molecule drug discovery of FGFR: A comprehensive review, Front. Chem. 10 (2022) Article ID 860985 (24 pages); https://doi.org/10.3389/fchem.2022.860985Search in Google Scholar

4M. Goldfarb, J. Schoorlemmer, A. Williams, S. Diwakar, Q. Wang, X. Huang, J. Giza, D. Tchetchik, K. Kelley, A. Vega, G. Matthews, P. Rossi, D. M. Ornitz and E. D’Angelo, Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels, Neuron 55 (2007) 449–463; https://doi.org/10.1016/j.neuron.2007.07.006Search in Google Scholar

5A. A. Belov and M. Mohammadi, Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology, Cold Spring Harb. Perspect. Biol. 5 (2013) Article ID a015958 (24 pages); https://doi.org/10.1101/cshperspect.a015958Search in Google Scholar

6D. M. Ornitz, FGFs, heparan sulfate and FGFRs: complex interactions essential for development, Bioessays 22 (2000) 108–112; https://doi.org/10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-MSearch in Google Scholar

7I. Fernandes-Freitas and B. M. Owen, Metabolic roles of endocrine fibroblast growth factors, Curr. Opin. Pharmacol. 25 (2015) 30–35; https://doi.org/https://doi.org/10.1016/j.coph.2015.09.014Search in Google Scholar

8N. K. Jain and K. S. Baghel, Selective cyclooxygenase-2 inhibitor etoricoxib attenuated hypoxic cancer milieu induced m2-polarization of macrophages and acquisition of pro-angiogenic and proinvasive attributes, Res. J. Pharm. Technol. 12 (2019) 5871–5877.Search in Google Scholar

9N. Wang, J.-Y. Li, S. Li, X.-C. Guo, T. Wu, W.-F. Wang and D.-S. Li, Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages, Biomed. Pharmacother. 108 (2018) 1825–1834; https://doi.org/10.1016/j.biopha.2018.09.143Search in Google Scholar

10A. Kommalapati, S. H. Tella, M. Borad, M. Javle and A. Mahipal, FGFR inhibitors in oncology: Insight on the management of toxicities in clinical practice, Cancers (Basel) 13(12) (2021) Article ID 2968 (18 pages); https://doi.org/10.3390/cancers13122968Search in Google Scholar

11F.-T. Liu, N.-G. Li, Y.-M. Zhang, W.-C. Xie, S.-P. Yang, T. Lu and Z.-H. Shi, Recent advance in the development of novel, selective and potent FGFR inhibitors, Eur. J. Med. Chem. 186 (2020) Article ID 111884; https://doi.org/10.1016/j.ejmech.2019.111884Search in Google Scholar

12R. J. Roskoski, The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder, Pharmacol. Res. 151 (2020) Article ID 104567 (91 pages); https://doi.org/10.1016/j.phrs.2019.104567Search in Google Scholar

13D. M. Ornitz and N. Itoh, The fibroblast growth factor signaling pathway, WIREs Dev. Biol. 4(3) (2015) 215–266; https://doi.org/10.1002/wdev.176Search in Google Scholar

14R. Dienstmann, J. Rodon, A. Prat, J. Perez-Garcia, B. Adamo, E. Felip, J. Cortes, A. J. Iafrate, P. Nuciforo and J. Tabernero, Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors, Ann. Oncol. 25 (2014) 552–563; https://doi.org/https://doi.org/10.1093/annonc/mdt419Search in Google Scholar

15D. Roy Burman, S. Das, C. Das and R. Bhattacharya, Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance, Mol. Biol. Rep. 48 (2021) 897–914; https://doi.org/10.1007/s11033-020-06094-ySearch in Google Scholar

16K. Holzmann, T. Grunt, C. Heinzle, S. Sampl, H. Steinhoff, N. Reichmann, M. Kleiter, M. Hauck and B. Marian, Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer, J. Nucleic Acids 2012 (2012) Article ID 950508 (13 pages); https://doi.org/10.1155/2012/950508Search in Google Scholar

17K. S. Baghel, B. N. Tewari, R. Shrivastava, S. A. Malik, M. U.-D. Lone, N. K. Jain, C. Tripathi, R. K. Kanchan, S. Dixit, K. Singh, K. Mitra, M. P. S. Negi, M. Srivastava, S. Misra, M. L. B. Bhatt and S. Bhadauria, Macrophages promote matrix protrusive and invasive function of breast cancer cells via MIP-1β dependent upregulation of MYO3A gene in breast cancer cells, Oncoimmunology 5 (2016) e1196299 (18 pages); https://doi.org/10.1080/2162402X.2016.1196299Search in Google Scholar

18M. A. Lemmon and J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell 141 (2010) 1117–1134; https://doi.org/10.1016/j.cell.2010.06.011Search in Google Scholar

19S. Mandal, S. Bandyopadhyay, K. Tyagi and A. Roy, Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis, Biochim. Biophys. Acta Rev. Cancer 1876(2) (2021) Article ID 188619; https://doi.org/10.1016/j.bbcan.2021.188619Search in Google Scholar

20M. Mossahebi-Mohammadi, M. Quan, J.-S. Zhang and X. Li, FGF signaling pathway: A key regulator of stem cell pluripotency, Front. Cell Dev. Biol. 8 (2020) Article ID 79 (10 pages); https://doi.org/10.3389/fcell.2020.00079Search in Google Scholar

21H. R. Ferguson, M. P. Smith and C. Francavilla, Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling, Cells 10(5) (2021) Article ID 1201 (35 pages); https://doi.org/10.3390/cells10051201Search in Google Scholar

22P. Dubey, R. Shrivastava, C. Tripathi, N. K. Jain, B. N. Tewari, M.-U.-D. Lone, K. S. Baghel, V. Kumar, S. Misra, S. Bhadauria and M. L. B. Bhatt, Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages, Cell. Mol. Biol. (Noisy-le-grand) 60 (2014) 10–15.Search in Google Scholar

23N. K. Jain, M. Tailang, H. K. Jain, B. Chandrasekaran, B. M. Sahoo, A. Subramanian, N. Thangavel, A. Aldahish, K. Chidambaram, M. Alagusundaram, S. Kumar and P. Selvam, Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review, Front. Pharmacol. 14 (2023) Article ID 1135145; https://doi.org/10.3389/fphar.2023.1135145Search in Google Scholar

24N. Su, M. Jin and L. Chen, Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models, Bone Res. 2 (2014) Article ID 14003 (24 pages); https://doi.org/10.1038/boneres.2014.3Search in Google Scholar

25M. Katoh, Fibroblast growth factor receptors as treatment targets in clinical oncology, Nat. Rev. Clin. Oncol. 16 (2019) 105–122; https://doi.org/10.1038/s41571-018-0115-ySearch in Google Scholar

26T. Helsten, S. Elkin, E. Arthur, B. N. Tomson, J. Carter and R. Kurzrock, The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing, Clin. Cancer Res. 22(1) (2016) 259–267; https://doi.org/10.1158/1078-0432.CCR-14-3212Search in Google Scholar

27W. Gu, J. Yang, Y. Wang, J. Xu, X. Wang, F. Du, X. Hu, H. Guo, C. Song, R. Tao and X. Zhang, Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing, Am. J. Cancer Res. 11 (2021) 3893–3906.Search in Google Scholar

28N. K. Jain, A. Agrawal, G. T. Kulkarni and M. Tailang, Molecular docking study on phytoconstituents of traditional ayurvedic drug Tulsi (Ocimum sanctum L.) against COVID-19 Mpro enzyme: An in silico study, Int. J. Pharm. Pharm. Sci. 14(4) (2022) 44–50; https://doi.org/10.22159/ijpps.2022v14i4.43181Search in Google Scholar

29R. Porta, R. Borea, A. Coelho, S. Khan, A. Araújo, P. Reclusa, T. Franchina, N. Van Der Steen, P. Van Dam, J. Ferri, R. Sirera, A. Naing, D. Hong and C. Rolfo, FGFR a promising druggable target in cancer: Molecular biology and new drugs, Crit. Rev. Oncol. Hematol. 113 (2017) 256–267; https://doi.org/10.1016/j.critrevonc.2017.02.018Search in Google Scholar

30M. Touat, E. Ileana, S. Postel-Vinay, F. André and J.-C. Soria, Targeting FGFR signaling in cancer, Clin. Cancer Res. 21(12) (2015) 2684–2694; https://doi.org/10.1158/1078-0432.CCR-14-2329Search in Google Scholar

31L. M. de Almeida Carvalho, S. de Oliveira Sapori Avelar, A. Haslam, J. Gill and V. Prasad, Estimation of percentage of patients with fibroblast growth factor receptor alterations eligible for off-label use of erdafitinib, JAMA Netw. Open 2(11) (2019) e1916091 (10 pages); https://doi.org/10.1001/jamanetworkopen.2019.16091Search in Google Scholar

32A. Weaver and J. B. Bossaer, Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class, J. Oncol. Pharm. Pract. 27(3) (2021) 702–710; https://doi.org/10.1177/1078155220983425Search in Google Scholar

33L. Huang, S. Jiang and Y. Shi, Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020), J. Hematol. Oncol. 13(1) (2020) Article ID 143 (23 pages); https://doi.org/10.1186/s13045-020-00977-0Search in Google Scholar

34R. Roskoski, Jr., Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes, Pharmacol. Res. 103 (2016) 26–48; https://doi.org/10.1016/j.phrs.2015.10.021Search in Google Scholar

35K. S. Bhullar, N. O. Lagarón, E. M. McGowan, I. Parmar, A. Jha, B. P. Hubbard and H. P. V. Rupasinghe, Kinase-targeted cancer therapies: progress, challenges and future directions, Mol. Cancer 17 (2018) Article ID 48 (20 pages); https://doi.org/10.1186/s12943-018-0804-2Search in Google Scholar

36R. Roskoski, Jr., Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update, Pharmacol. Res. 187 (2023) Article ID 106552 (21 pages); https://doi.org/10.1016/j.phrs.2022.106552Search in Google Scholar

37P. R. Gavine, L. Mooney, E. Kilgour, A. P. Thomas, K. Al-Kadhimi, S. Beck, C. Rooney, T. Coleman, D. Baker, M. J. Mellor, A. N. Brooks and T. Klinowska, AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family, Cancer Res. 72 (2012) 2045–2056; https://doi.org/10.1158/0008-5472.CAN-11-3034Search in Google Scholar

38J. A. Tucker, T. Klein, J. Breed, A. L. Breeze, R. Overman, C. Phillips and R. A. Norman, Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4, Structure 22 (2014) 1764–1774; https://doi.org/10.1016/j.str.2014.09.019Search in Google Scholar

39A. Tyulyandina, D. Harrison, W. Yin, E. Stepanova, D. Kochenkov, E. Solomko, N. Peretolchina, F. Daeyaert, J.-B. Joos, K. Van Aken, M. Byakhov, E. Gavrilova, S. Tjulandin and I. Tsimafeyeu, Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies, Invest. New Drugs 35 (2017) 127–133; https://doi.org/10.1007/s10637-016-0404-1Search in Google Scholar

40C. Herbert, U. Schieborr, K. Saxena, J. Juraszek, F. De Smet, C. Alcouffe, M. Bianciotto, G. Saladino, D. Sibrac, D. Kudlinzki, S. Sreeramulu, A. Brown, P. Rigon, J.-P. Herault, G. Lassalle, T. L. Blundell, F. Rousseau, A. Gils, J. Schymkowitz, P. Tompa, J.-M. Herbert, P. Carmeliet, F. L. Gervasio, H. Schwalbe and F. Bono, Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling., Cancer Cell 23 (2013) 489–501; https://doi.org/10.1016/j.ccr.2013.02.018Search in Google Scholar

41H. Patani, T. D. Bunney, N. Thiyagarajan, R. A. Norman, D. Ogg, J. Breed, P. Ashford, A. Potterton, M. Edwards, S. V. Williams, G. S. Thomson, C. S. M. Pang, M. A. Knowles, A. L. Breeze, C. Orengo, C. Phillips and M. Katan, Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use, Oncotarget 7 (2016) 24252–24268; https://doi.org/10.18632/oncotarget.8132Search in Google Scholar

42T. P. S. Perera, E. Jovcheva, L. Mevellec, J. Vialard, D. De Lange, T. Verhulst, C. Paulussen, K. Van De Ven, P. King, E. Freyne, D. C. Rees, M. Squires, G. Saxty, M. Page, C. W. Murray, R. Gilissen, G. Ward, N. T. Thompson, D. R. Newell, N. Cheng, L. Xie, J. Yang, S. J. Platero, J. D. Karkera, C. Moy, P. Angibaud, S. Laquerre and M. V. Lorenzi, Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor, Mol. Cancer Ther. 16 (2017) 1010–1020; https://doi.org/10.1158/1535-7163.MCT-16-0589Search in Google Scholar

43R. Roskoski, Jr., Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update, Pharmacol. Res. 152 (2020) Article ID 104609; https://doi.org/10.1016/j.phrs.2019.104609Search in Google Scholar

44M. Verstraete, A. Debucquoy, A. Gonnissen, R. Dok, S. Isebaert, E. Devos, W. McBride and K. Haustermans, In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer, BMC Cancer 15 (2015) Article ID 946 (11 pages); https://doi.org/10.1186/s12885-015-2000-8Search in Google Scholar

45Y. Loriot, A. Necchi, S. H. Park, J. Garcia-Donas, R. Huddart, E. Burgess, M. Fleming, A. Rezazadeh, B. Mellado, S. Varlamov, M. Joshi, I. Duran, S. T. Tagawa, Y. Zakharia, B. Zhong, K. Stuyckens, A. Santiago-Walker, P. De Porre, A. O’Hagan, A. Avadhani and A. O. Siefker-Radtke (for BLC2001 study group), Erdafitinib in locally advanced or metastatic urothelial carcinoma., N. Engl. J. Med. 381 (2019) 338–348; https://doi.org/10.1056/NEJMoa1817323Search in Google Scholar

46A. O. Siefker-Radtke, A. Necchi, S. H. Park, J. García-Donas, R. A. Huddart, E. F. Burgess, M. T. Fleming, A. Rezazadeh Kalebasty, B. Mellado, S. Varlamov, M. Joshi, I. Duran, S. T. Tagawa, Y. Zakharia, S. Akapame, A. E. Santiago-Walker, M. Monga, A. O’Hagan and Y. Loriot (for BLC2001 study group), Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study, Lancet Oncol. 23 (2022) 248–258; https://doi.org/10.1016/S1470-2045(21)00660-4Search in Google Scholar

47X. Zheng, H. Wang, J. Deng, M. Yao, X. Zou, F. Zhang and X. Ma, Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis, Front. Oncol. 12 (2023) Article ID 907377 (16 pages); https://doi.org/10.3389/fonc.2022.907377Search in Google Scholar

48A.-G. Dosne, E. Valade, N. Goeyvaerts, P. De Porre, A. Avadhani, A. O’Hagan, L. Y. Li, D. Ouellet and J. J. Perez Ruixo, Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma, Cancer Chemother. Pharmacol. 89 (2022) 151–164; https://doi.org/10.1007/s00280-021-04381-4Search in Google Scholar

49A. Markham, Erdafitinib: First global approval, Drugs 79 (2019) 1017–1021; https://doi.org/10.1007/s40265-019-01142-9Search in Google Scholar

50J. Tabernero, R. Bahleda, R. Dienstmann, J. R. Infante, A. Mita, A. Italiano, E. Calvo, V. Moreno, B. Adamo, A. Gazzah, B. Zhong, S. J. Platero, J. W. Smit, K. Stuyckens, M. Chatterjee-Kishore, J. Rodon, V. Peddareddigari, F. R. Luo and J.-C. Soria, Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors, J. Clin. Oncol. 33 (2015) 3401–3408; https://doi.org/10.1200/JCO.2014.60.7341Search in Google Scholar

51R. Bahleda, A. Italiano, C. Hierro, A. Mita, A. Cervantes, N. Chan, M. Awad, E. Calvo, V. Moreno, R. Govindan, A. Spira, M. Gonzalez, B. Zhong, A. Santiago-Walker, I. Poggesi, T. Parekh, H. Xie, J. Infante and J. Tabernero, Multicenter phase i study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors, Clin. Cancer Res. 25 (2019) 4888–4897; https://doi.org/10.1158/1078-0432.CCR-18-3334Search in Google Scholar

52E. Valade, A.-G. Dosne, H. Xie, R. Kleiman, L. Y. Li, J. J. Perez-Ruixo and D. Ouellet, Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors, Cancer Chemother. Pharmacol. 84 (2019) 621–633; https://doi.org/10.1007/s00280-019-03896-1Search in Google Scholar

53T. Nishina, S. Takahashi, R. Iwasawa, H. Noguchi, M. Aoki and T. Doi, Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors, Invest. New Drugs 36 (2018) 424–434; https://doi.org/10.1007/s10637-017-0514-4Search in Google Scholar

54E. Liow, N. Howard, C.-H. Jung, B. Pope, B. K. Campbell, A. Nguyen, M. Kerger, J. B. Ruddle, A. Anton, B. Thomas, K. Chu, P. Dundee, J. S. Peters, A. J. Costello, A. S. Ryan, C. M. Hovens, B. Tran and N. M. Corcoran, Phase 2 study of neoadjuvant FGFR inhibition and androgen deprivation therapy prior to prostatectomy, Clin. Genitourin. Cancer 20 (2022) 452–458; https://doi.org/10.1016/j.clgc.2022.05.007Search in Google Scholar

55E. Scheers, C. Borgmans, C. Keung, H. Bohets, I. Wynant, I. Poggesi, F. Cuyckens, L. Leclercq and R. N. V. S. Mamidi, Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, Xenobiotica 51 (2021) 177–193; https://doi.org/10.1080/00498254.2020.1821123Search in Google Scholar

56I. Poggesi, L. Y. Li, J. Jiao, P. Hellemans, F. Rasschaert, L. de Zwart, J. Snoeys, M. De Meulder, R. N. V. S. Mamidi and D. Ouellet, Effect of fluconazole and itraconazole on the pharmacokinetics of erdafitinib in healthy adults: A randomized, open-label, drug-drug interaction study, Eur. J. Drug Metab. Pharmacokin. 45 (2020) 101–111; https://doi.org/10.1007/s13318-019-00581-9Search in Google Scholar

57L. Y. Li, Y. Guo, M. Gonzalez and D. Ouellet, Effect of plasma protein binding on the pharmacokinetics of erdafitinib: Results of an integrated cross-study analysis, J. Clin. Pharmacol. 60 (2020) 391–399; https://doi.org/10.1002/jcph.1529Search in Google Scholar

58L. Wu, C. Zhang, C. He, D. Qian, L. Lu, Y. Sun, M. Xu, J. Zhuo, P. C. C. Liu, R. Klabe, R. Wynn, M. Covington, K. Gallagher, L. Leffet, K. Bowman, S. Diamond, H. Koblish, Y. Zhang, M. Soloviev, G. Hollis, T. C. Burn, P. Scherle, S. Yeleswaram, R. Huber and W. Yao, Discovery of pemigatinib: A potent and selective fibroblast growth factor receptor (FGFR) inhibitor, J. Med. Chem. 64 (2021) 10666–10679; https://doi.org/10.1021/acs.jmedchem.1c00713Search in Google Scholar

59P. C. C. Liu, H. Koblish, L. Wu, K. Bowman, S. Diamond, D. DiMatteo, Y. Zhang, M. Hansbury, M. Rupar, X. Wen, P. Collier, P. Feldman, R. Klabe, K. A. Burke, M. Soloviev, C. Gardiner, X. He, A. Volgina, M. Covington, B. Ruggeri, R. Wynn, T. C. Burn, P. Scherle, S. Yeleswaram, W. Yao, R. Huber and G. Hollis, INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models, PLoS One 15 (2020) e0231877 (16 pages); https://doi.org/10.1371/journal.pone.0231877Search in Google Scholar

60Q. Lin, X. Chen, L. Qu, M. Guo, H. Wei, S. Dai, L. Jiang and Y. Chen, Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants, Commun. Chem. 5 (2022) Article ID 100 (7 pages); https://doi.org/10.1038/s42004-022-00718-zSearch in Google Scholar

61V. Subbiah, N. O. Iannotti, M. Gutierrez, D. C. Smith, L. Féliz, C. F. Lihou, C. Tian, I. M. Silverman, T. Ji and M. Saleh, FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies, Ann. Oncol. 33(5) (2022) 522–533; https://doi.org/10.1016/j.annonc.2022.02.001Search in Google Scholar

62M. Saleh, M. E. Gutierrez, V. Subbiah, D. C. Smith, E. Asatiani, C. F. Lihou, H. Zhen, S. Yeleswaram, T. Ji and J. Nemunaitis, Abstract CT111: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies, Cancer Res. 77(13, Suppl.) (2017) CT111; https://doi.org/10.1158/1538-7445.AM2017-CT111Search in Google Scholar

63X. Gong, T. Ji, X. Liu, X. Chen and S. Yeleswaram, Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies, Pharmacol. Res. Perspect. 10 (2022) e00906 (8 pages); https://doi.org/10.1002/prp2.906Search in Google Scholar

64G. K. Abou-Alfa, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, A. S. Paulson, M. J. Borad, D. Gallinson, A. G. Murphy, D.-Y. Oh, E. Dotan, D. V Catenacci, E. Van Cutsem, T. Ji, C. F. Lihou, H. Zhen, L. Féliz and A. Vogel, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol. 21 (2020) 671–684; https://doi.org/10.1016/S1470-2045(20)30109-1Search in Google Scholar

65S. M. Hoy, Pemigatinib: First approval, Drugs 80 (2020) 923–929; https://doi.org/10.1007/s40265-020-01330-ySearch in Google Scholar

66U.S. Food & Drug Adminstration, FDA Approves Pemigatinib for Relapsed or Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement, USFDA, Aug 29, 2022; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms-fgfr1-rearrangement; last access date Oct 10, 2023Search in Google Scholar

67C. Kang, Infigratinib: First approval, Drugs 81 (2021) 1355–1360; https://doi.org/10.1007/s40265-021-01567-1Search in Google Scholar

68Y. Y. Syed, Futibatinib: First approval, Drugs 82 (2022) 1737–1743; https://doi.org/10.1007/s40265-022-01806-zSearch in Google Scholar

69K. Bibeau, L. Féliz, C. F. Lihou, H. Ren and G. K. Abou-Alfa, Progression-free survival in patients with cholangiocarcinoma with or without FGF/FGFR alterations: A FIGHT-202 post hoc analysis of prior systemic therapy response, JCO Prec. Oncol. 6 (2022) e2100414; https://doi.org/10.1200/PO.21.00414Search in Google Scholar

70T. S. Bekaii-Saab, J. W. Valle, E. Van Cutsem, L. Rimassa, J. Furuse, T. Ioka, D. Melisi, T. Macarulla, J. Bridgewater, H. Wasan, M. J. Borad, G. K. Abou-Alfa, P. Jiang, C. F. Lihou, H. Zhen, E. Asatiani, L. Féliz and A. Vogel, FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements, Future Oncol. 16 (2020) 2385–2399; https://doi.org/10.2217/fon-2020-0429Search in Google Scholar

71S. Verstovsek, A. M. Vannucchi, A. Rambaldi, J. R. Gotlib, A. J. Mead, A. Hochhaus, J.-J. Kiladjian, J. C. Hernandez Boluda, E. Asatiani, C. Lihou, H. Zhen and A. Reiter, Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1), Blood 132(Suppl. 1) (2018) Article ID 690; https://doi.org/10.1182/blood-2018-99-110388Search in Google Scholar

72J. Gotlib, J.-J. Kiladjian, A. Vannucchi, A. Rambaldi, A. Reiter, W. Shomali, T. I. George, J. L. Patel, P. Colucci, C. Walker, H. Zhen and S. Verstovsek, A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1), Blood 138(Suppl. 1) (2021) Article ID 385; https://doi.org/10.1182/blood-2021-148103Search in Google Scholar

73T. Ji, X. Chen, X. Liu and S. Yeleswaram, Population pharmacokinetics analysis of pemigatinib in patients with advanced malignancies, Clin. Pharmacol. Drug Dev. 11 (2022) 454–466; https://doi.org/10.1002/cpdd.1038Search in Google Scholar

74T. Ji, K. Rockich, N. Epstein, H. Overholt, P. Wang, X. Chen, N. Punwani and S. Yeleswaram, Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function, Br. J. Clin. Pharmacol. 88 (2022) 237–247; https://doi.org/10.1111/bcp.14954Search in Google Scholar

75T. Ji, K. Rockich, N. Epstein, H. Overholt, P. Wang, X. Chen, N. Punwani and S. Yeleswaram, Evaluation of drug-drug interactions of pemigatinib in healthy participants, Eur. J. Clin. Pharmacol. 77 (2021) 1887–1897; https://doi.org/10.1007/s00228-021-03184-zSearch in Google Scholar

76V. Guagnano, P. Furet, C. Spanka, V. Bordas, M. Le Douget, C. Stamm, J. Brueggen, M. R. Jensen, C. Schnell, H. Schmid, M. Wartmann, J. Berghausen, P. Drueckes, A. Zimmerlin, D. Bussiere, J. Murray and D. Graus Porta, Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase, J. Med. Chem. 54 (2011) 7066–7083; https://doi.org/10.1021/jm2006222Search in Google Scholar

77V. Guagnano, A. Kauffmann, S. Wöhrle, C. Stamm, M. Ito, L. Barys, A. Pornon, Y. Yao, F. Li, Y. Zhang, Z. Chen, C. J. Wilson, V. Bordas, M. Le Douget, L. A. Gaither, J. Borawski, J. E. Monahan, K. Venkatesan, T. Brummendorf, D. M. Thomas, C. Garcia-Echeverria, F. Hofmann, W. R. Sellers and D. Graus-Porta, FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor, Cancer Discov. 2 (2012) 1118–1133; https://doi.org/10.1158/2159-8290.CD-12-0210Search in Google Scholar

78L. Nogova, L. V. Sequist, J. M. Perez Garcia, F. Andre, J.-P. Delord, M. Hidalgo, J. H. M. Schellens, P. A. Cassier, D. R. Camidge, M. Schuler, U. Vaishampayan, H. Burris, G. G. Tian, M. Campone, Z. A. Wainberg, W.-T. Lim, P. LoRusso, G. I. Shapiro, K. Parker, X. Chen, S. Choudhury, F. Ringeisen, D. Graus-Porta, D. Porter, R. Isaacs, R. Buettner and J. Wolf, Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion study, J. Clin. Oncol. 35 (2017) 157–165; https://doi.org/10.1200/JCO.2016.67.2048Search in Google Scholar

79C. M. Kelly, A. N. Shoushtari, L.-X. Qin, S. P. D’Angelo, M. A. Dickson, M. M. Gounder, M. L. Keohan, C. Mcfadyen, A. Sjoberg, S. Singer, R. P. DeMatteo, S. Hwang, M. H. Heinemann, J. H. Francis, C. R. Antonescu, P. Chi and W. D. Tap, A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor, Invest. New Drugs 37 (2019) 282–290; https://doi.org/10.1007/s10637-018-0648-zSearch in Google Scholar

80M. Javle, M. Lowery, R. T. Shroff, K. H. Weiss, C. Springfeld, M. J. Borad, R. K. Ramanathan, L. Goyal, S. Sadeghi, T. Macarulla, A. El-Khoueiry, R. K. Kelley, I. Borbath, S. P. Choo, D.-Y. Oh, P. A. Philip, L.-T. Chen, T. Reungwetwattana, E. V. Cutsem, K.-H. Yeh, K. Ciombor, R. S. Finn, A. Patel, S. Sen, D. Porter, R. Isaacs, A. X. Zhu, G. K. Abou-Alfa and T. Bekaii-Saab, Phase II study of BGJ398 in patients with fgfr-altered advanced cholangiocarcinoma, J. Clin. Oncol. 36 (2018) 276–282; https://doi.org/10.1200/JCO.2017.75.5009Search in Google Scholar

81M. Javle, S. Roychowdhury, R. K. Kelley, S. Sadeghi, T. Macarulla, K. H. Weiss, D.-T. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, M. J. Borad, W. P. Yong, P. A. Philip, M. Bitzer, S. Tanasanvimon, A. Li, A. Pande, H. S. Soifer, S. P. Shepherd, S. Moran, A. X. Zhu, T. S. Bekaii-Saab and G. K. Abou-Alfa, Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, Lancet Gastroenterol. Hepatol. 6 (2021) 803–815; https://doi.org/10.1016/S2468-1253(21)00196-5Search in Google Scholar

82S. Makawita, G. K Abou-Alfa, S. Roychowdhury, S. Sadeghi, I. Borbath, L. Goyal, A. Cohn, A. Lamarca, D.-Y. Oh, T. Macarulla, R. T Shroff, M. Howland, A. Li, T. Cho, A. Pande and M. Javle, Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial, Future Oncol. 16 (2020) 2375–2384; https://doi.org/10.2217/fon-2020-0299Search in Google Scholar

83Y. Lyou, P. Grivas, J. E. Rosenberg, J. Hoffman-Censits, D. I. Quinn, D. P. Petrylak, M. Galsky, U. Vaishampayan, U. De Giorgi, S. Gupta, H. Burris, J. Rearden, A. Li, H. Wang, M. Reyes, S. Moran, S. Daneshmand, D. Bajorin and S. K. Pal, Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1-3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma, Eur. Urol. 78 (2020) 916–924; https://doi.org/https://doi.org/10.1016/j.eururo.2020.08.002Search in Google Scholar

84S. K. Pal, D. M. Somford, P. Grivas, S. S. Sridhar, S. Gupta, J. Bellmunt, G. Sonpavde, M. T. Fleming, S. P. Lerner, Y. Loriot, J. Hoffman-Censits, B. P. Valderrama, C. Andresen, M. J. Schnabel, S. Cole and S. Daneshmand, Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial, Future Oncol. 18 (2022) 2599–2614; https://doi.org/10.2217/fon-2021-1629Search in Google Scholar

85A. B. Lassman, J. M. Sepúlveda-Sánchez, T. F. Cloughesy, M. J. Gil-Gil, V. K. Puduvalli, J. J. Raizer, F. Y. F. De Vos, P. Y. Wen, N. A. Butowski, P. M. J. Clement, M. D. Groves, C. Belda-Iniesta, P. Giglio, H. S. Soifer, S. Rowsey, C. Xu, F. Avogadri, G. Wei, S. Moran and P. Roth, Infigratinib in patients with recurrent gliomas and FGFR alterations: A multicenter phase II study, Clin. Cancer Res. 28 (2022) 2270–2277; https://doi.org/10.1158/1078-0432.CCR-21-2664Search in Google Scholar

86N. S. Al-Shakliah, M. W. Attwa, A. A. Kadi and H. AlRabiah, Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites, RSC Adv. 10 (2020) 16231–16244; https://doi.org/10.1039/C9RA10871HSearch in Google Scholar

87H. Sootome, H. Fujita, K. Ito, H. Ochiiwa, Y. Fujioka, K. Ito, A. Miura, T. Sagara, S. Ito, H. Ohsawa, S. Otsuki, K. Funabashi, M. Yashiro, K. Matsuo, K. Yonekura and H. Hirai, Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors, Cancer Res. 80 (2020) 4986–4997; https://doi.org/10.1158/0008-5472.CAN-19-2568Search in Google Scholar

88M. Kalyukina, Y. Yosaatmadja, M. J. Middleditch, A. V Patterson, J. B. Smaill and C. J. Squire, TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor&emsp14;1 (FGFR1) irreversible structure, ChemMedChem 14 (2019) 494–500; https://doi.org/10.1002/cmdc.201800719Search in Google Scholar

89R. Bahleda, F. Meric-Bernstam, L. Goyal, B. Tran, Y. He, I. Yamamiya, K. A. Benhadji, I. Matos and H.-T. Arkenau, Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors, Ann. Oncol. 31(10) (2020) 1405–1412; https://doi.org/10.1016/j.annonc.2020.06.018Search in Google Scholar

90F. Meric-Bernstam, R. Bahleda, C. Hierro, M. Sanson, J. Bridgewater, H.-T. Arkenau, B. Tran, R. K. Kelley, J. O. Park, M. Javle, Y. He, K. A. Benhadji and L. Goyal, Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase i dose-expansion study, Cancer Discov. 12 (2022) 402–415; https://doi.org/10.1158/2159-8290.CD-21-0697Search in Google Scholar

91L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane, J. W. Valle, T. B. Karasic, T. A. Abrams, R. K. Kelley, P. Cassier, J. Furuse, H.-J. Klümpen, H.-M. Chang, L.-T. Chen, Y. Komatsu, K. Masuda, D. Ahn, Y. He, N. Soni, K. A. Benhadji and J. A. Bridgewater, Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangio-carcinoma (iCCA) with FGFR2 fusions/rearrangements, Cancer Res. 81 (2021) CT010–CT010; https://doi.org/10.1158/1538-7445.AM2021-CT010Search in Google Scholar

92I. Yamamiya, A. Hunt, F. Yamashita, D. Sonnichsen, T. Muto, Y. He and K. A. Benhadji, Evaluation of the mass balance and metabolic profile of futibatinib in healthy participants, Clin. Pharmacol. Drug Dev. 12 (2023) 927–939; https://doi.org/10.1002/cpdd.1271Search in Google Scholar

93I. Yamamiya, A. Hunt, F. Yamashita, D. Sonnichsen, Y. He and K. A. Benhadji, Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib, Clin. Pharmacol. Drug Dev. 12(3) (2022) 294–303; https://doi.org/10.1002/cpdd.1196Search in Google Scholar

94I. Yamamiya, A. Hunt, T. Takenaka, D. Sonnichsen, M. Mina, Y. He, K. A. Benhadji and L. Gao, Evaluation of the cytochrome P450 3A and P-glycoprotein drug-drug interaction potential of futibatinib, Clin. Pharmacol. Drug Dev. 12(10) (2023) 966–978; https://doi.org/10.1002/cpdd.1259Search in Google Scholar

95I. Yamamiya, A. Hunt, F. Yamashita, D. Sonnichsen, Y. He and K. A. Benhadji, Evaluation of potential food effects and drug interactions with lansoprazole in healthy adult volunteers receiving futibatinib, Clin. Pharmacol. Drug Dev. 12(3) (2023) 294–303; https://doi.org/10.1002/cpdd.1196Search in Google Scholar

96A. Jain, M. J. Borad, R. K. Kelley, Y. Wang, R. Abdel-Wahab, F. Meric-Bernstam, K. A. Baggerly, A. O. Kaseb, H. O. Al-Shamsi, D. H. Ahn, T. DeLeon, A. G. Bocobo, T. Bekaii-Saab, R. T. Shroff and M. Javle, Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype, JCO Prec. Oncol. 2 (2018) 1–12; https://doi.org/10.1200/PO.17.00080Search in Google Scholar

97P. C. Lee, A. Hendifar, A. Osipov, M. Cho, D. Li and J. Gong, Targeting the fibroblast growth factor receptor (FGFR) in advanced cholangiocarcinoma: Clinical trial progress and future considerations, Cancers (Basel) 13(7) (2021) Article ID 1706; https://doi.org/10.3390/cancers13071706Search in Google Scholar

98A. Saborowski, U. Lehmann and A. Vogel, FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?, Ther. Adv. Med. Oncol. 12 (2020) 1–12; https://doi.org/10.1177/1758835920953293Search in Google Scholar

99V. Mazzaferro, B. F. El-Rayes, M. Droz Dit Busset, C. Cotsoglou, W. P. Harris, N. Damjanov, G. Masi, L. Rimassa, N. Personeni, F. Braiteh, V. Zagonel, K. P. Papadopoulos, T. Hall, Y. Wang, B. Schwartz, J. Kazakin, S. Bhoori, F. de Braud and W. L. Shaib, Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, Br. J. Cancer 120 (2019) 165–171; https://doi.org/10.1038/s41416-018-0334-0Search in Google Scholar

100J. Gandhi, J.-F. Chen and H. Al-Ahmadie, Urothelial carcinoma: Divergent differentiation and morphologic subtypes, Surg. Pathol. Clin. 15 (2022) 641–659; https://doi.org/10.1016/j.path.2022.07.003Search in Google Scholar

101Z. B. Zengin, A. Chehrazi-Raffle, N. J. Salgia, R. Muddasani, S. Ali, L. Meza and S. K. Pal, Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma, Urol. Oncol. 40 (2022) 25–36; https://doi.org/10.1016/j.urolonc.2021.10.003Search in Google Scholar

102C. N. Sternberg, D. P. Petrylak, J. Bellmunt, H. Nishiyama, A. Necchi, H. Gurney, J.-L. Lee, M. S. van der Heijden, E. Rosenbaum, N. Penel, S.-T. Pang, J.-R. Li, X. García Del Muro, F. Joly, Z. Pápai, W. Bao, P. Ellinghaus, C. Lu, M. Sierecki, S. Coppieters, K. Nakajima, T. C. Ishida and D. I. Quinn, FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression, J. Clin. Oncol. 41 (2023) 629–639; https://doi.org/10.1200/JCO.21.02303Search in Google Scholar

103B. J. Bain, Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1, Haematologica 95(5) (2010) 696–698; https://doi.org/10.3324/haematol.2009.021675Search in Google Scholar

104S. Yue, Y. Li, X. Chen, J. Wang, M. Li, Y. Chen and D. Wu, FGFR-TKI resistance in cancer: current status and perspectives, J. Hematol. Oncol. 14 (2021) Article ID 23 (14 pages); https://doi.org/10.1186/s13045-021-01040-2Search in Google Scholar

105M. H. Voss, C. Hierro, R. S. Heist, J. M. Cleary, F. Meric-Bernstam, J. Tabernero, F. Janku, L. Gandhi, A. J. Iafrate, D. R. Borger, N. Ishii, Y. Hu, Y. Kirpicheva, V. Nicolas-Metral, A. Pokorska-Bocci, A. Vaslin Chessex, C. Zanna, K. T. Flaherty and J. Baselga, A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations, Clin. Cancer Res. 25 (2019) 2699–2707; https://doi.org/10.1158/1078-0432.CCR-18-1959Search in Google Scholar

106Y. Chiba, K. Sudo, Y. Kojima, H. Okuma, S. Kohsaka, R. Machida, M. Ichimura, K. Anjo, K. Kurishita, N. Okita, K. Nakamura, I. Kinoshita, M. Takahashi, J. Matsubara, H. Kusaba, K. Yonemori and M. Takahashi, A multicenter investigator-initiated phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial, BMC Cancer 22 (2022) Article ID 869 (7 pages); https://doi.org/10.1186/s12885-022-09949-8Search in Google Scholar

107G. E. Konecny, N. Finkler, A. A. Garcia, D. Lorusso, P. S. Lee, R. P. Rocconi, P. C. Fong, M. Squires, K. Mishra, A. Upalawanna, Y. Wang and R. Kristeleit, Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a nonrandomised, open-label, two-group, two-stage, phase 2 study, Lancet Oncol. 16 (2015) 686–694; https://doi.org/10.1016/S1470-2045(15)70159-2Search in Google Scholar

108H. Kanzaki, T. Chiba, J. Ao, K. Koroki, K. Kanayama, S. Maruta, T. Maeda, Y. Kusakabe, K. Kobayashi, N. Kanogawa, S. Kiyono, M. Nakamura, T. Kondo, T. Saito, R. Nakagawa, S. Ogasawara, E. Suzuki, Y. Ooka, R. Muroyama, S. Nakamoto, S. Yasui, A. Tawada, M. Arai, T. Kanda, H. Maruyama, N. Mimura, J. Kato, Y. Zen, M. Ohtsuka, A. Iwama and N. Kato, The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma, Sci. Rep. 11 (2021) Article ID 5303 (12 pages); https://doi.org/10.1038/s41598-021-84117-9Search in Google Scholar

109A. Raja, I. Park, F. Haq and S.-M. Ahn, FGF19-FGFR4 signaling in hepatocellular carcinoma, Cells 8(6) (2019) Article ID 536 (16 pages); https://doi.org/10.3390/cells8060536Search in Google Scholar

110S. L. Chan, M. Schuler, Y.-K. Kang, C.-J. Yen, J. Edeline, S. P. Choo, C.-C. Lin, T. Okusaka, K.-H. Weiss, T. Macarulla, S. Cattan, J.-F. Blanc, K.-H. Lee, M. Maur, S. Pant, M. Kudo, E. Assenat, A. X. Zhu, T. Yau, H. Y. Lim, J. Bruix, A. Geier, C. Guillen-Ponce, A. Fasolo, R. S. Finn, J. Fan, A. Vogel, S. Qin, M. Riester, V. Katsanou, M. Chaudhari, T. Kakizume, Y. Gu, D. G. Porta, A. Myers and J.-P. Delord, A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors, J. Exp. Clin. Cancer Res. 41 (2022) Article ID 189 (19 pages); https://doi.org/10.1186/s13046-022-02383-5Search in Google Scholar

111L. Goyal, L. Shi, L. Y. Liu, F. Fece de la Cruz, J. K. Lennerz, S. Raghavan, I. Leschiner, L. Elagina, G. Siravegna, R. W. S. Ng, P. Vu, K. C. Patra, S. K. Saha, R. N. Uppot, R. Arellano, S. Reyes, T. Sagara, S. Otsuki, B. Nadres, H. A. Shahzade, I. Dey-Guha, I. J. Fetter, I. Baiev, E. E. V. Seventer, J. E. Murphy, C. R. Ferrone, K. K. Tanabe, V. Deshpande, J. J. Harding, R. Yaeger, R. K. Kelley, A. Bardelli, A. J. Iafrate, W. C. Hahn, C. H. Benes, D. T. Ting, H. Hirai, G. Getz, D. Juric, A. X. Zhu, R. B. Corcoran and N. Bardeesy, TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma, Cancer Discov. 9 (2019) 1064–1079; https://doi.org/10.1158/2159-8290.CD-19-0182Search in Google Scholar